University of Cincinnati Dept of Oncology
Welcome,         Profile    Billing    Logout  
 2 Trials 
10 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Morris, John C
LIBRETTO-001, NCT03157128 / 2017-000800-59: A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer

Hourglass Apr 2022 - Dec 2022 : Approval in China for RET+NSCLC, medullary thyroid cancer and thyroid cancer
Hourglass Jan 2022 - Dec 2022 : Submission for lung cancer
Checkmark From LIBRETTO-001 trial in RET fusion-positive NSCLC
Aug 2020 - Aug 2020: From LIBRETTO-001 trial in RET fusion-positive NSCLC
Checkmark Granted for advanced RET fusion+ve 2L thyroid cancer [LIBRETTO-001]
More
Active, not recruiting
1/2
856
Europe, Canada, Japan, US, RoW
LOXO-292, Selpercatinib, LY3527723
Loxo Oncology, Inc., Eli Lilly and Company
Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
02/25
02/26
NCT03529539: Expanded Access for PSV Personalized Oncolytic Viruses

No Longer Available
N/A
NA
PSV
EpicentRx, Inc.
Cancer
 
 
NCT03906331: Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

Approved for marketing
N/A
Europe, Japan, US, RoW
Selpercatinib, LOXO-292, LY3527723
Eli Lilly and Company, Eli Lilly and Company
Non Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Breast Cancer, Pancreatic Cancer, Papillary Thyroid Cancer, Other Solid Tumors With Evidence of Activating RET Alteration
 
 
Herzog, Thomas J
AIM2CERV, NCT02853604 / 2015-004844-20: Study of ADXS11-001 in Participants With High Risk Locally Advanced Cervical Cancer

Terminated
3
110
Europe, Canada, US, RoW
ADXS11-001, Placebo
Advaxis, Inc., Gynecologic Oncology Group
High Risk Cervical Cancer, Advanced Cervical Cancer
07/19
07/19
EPIK-O, NCT04729387 / 2019-004682-40: Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

Active, not recruiting
3
358
Europe, Canada, US, RoW
Alpelisib, BYL719, Olaparib, Paclitaxel, Pegylated liposomal doxorubicin (PLD)
Novartis Pharmaceuticals
Ovarian Cancer
04/23
06/25
CG03, NCT03949283: Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer

Active, not recruiting
3
150
US
ChemoID Assay, Chemotherapeutic drug cytotoxicity assay of cancer stem cells (CSCs), Standard Chemotherapy, Chemotherapy
Cordgenics, LLC
Recurrent Ovarian Carcinoma, Platinum-resistant Ovarian Cancer
06/24
12/24
PROFECTA-II, NCT04374630: Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian

Completed
2
150
US, RoW
Paclitaxel, Afuresertib, LAE002
Laekna Limited
Platinum-resistant Ovarian Cancer
07/23
06/24
Burns, Gena
EPIK-O, NCT04729387 / 2019-004682-40: Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

Active, not recruiting
3
358
Europe, Canada, US, RoW
Alpelisib, BYL719, Olaparib, Paclitaxel, Pegylated liposomal doxorubicin (PLD)
Novartis Pharmaceuticals
Ovarian Cancer
04/23
06/25
NCT05817045: Evaluation of the RD-X19 Treatment Device in Individuals With Mild COVID-19

Completed
N/A
330
US
RD-X19, Sham
EmitBio Inc.
COVID-19
06/24
06/24
NCT05672875: Evaluation of the SRI B. Anthracis Lethal Factor Diagnostic System

Terminated
N/A
343
US
Anthrax LF Dx System
SRI International, Department of Health and Human Services
Anthrax
04/23
04/23

Download Options